Connect
MJA
MJA

Hepatitis C in Australia — a role for general practitioners?

Mieke L van Driel, David Lim and Paul J Clark
Med J Aust 2017; 207 (2): 53. || doi: 10.5694/mja17.00323

The availability of new antiviral agents opens the way for increasing GP involvement in the management of hepatitis C

The new direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infections became available on the Pharmaceutical Benefits Scheme in March 2016. In September 2016, already over 10% of the estimated 230 500 Australians with chronic HCV infection had been treated.1 While such rapid uptake was unanticipated, it may represent the low-hanging fruit of the HCV epidemic: patients already enlisted in tertiary clinics waiting for treatment. From an epidemiological perspective, the remaining untreated patients may fall under the radar of tertiary-based clinics. If Australia is to capitalise on the opportunities of universal access to DAA therapies, it will require the concerted efforts of general practitioners to improve rates of diagnosis, assessment, treatment and follow-up in the community.

  • Mieke L van Driel1
  • David Lim2
  • Paul J Clark1

  • 1 University of Queensland, Brisbane, QLD
  • 2 Flinders Rural Health South Australia, Victor Harbor, SA

Correspondence: m.vandriel@uq.edu.au

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.